Replies to post #30454 on Intellipharmaceutics International Inc. (IPCI)

[doogdilinger]

I'll be the 1st to admit that I'm mistaken if anyone can prove to me and/or show me where I'm wrong...but for me the Bloomberg reported PAR/FocalinXR sales for IPCI's fiscal Q2 and fiscal Q3 periods don't even remotely match up to the actual revenue numbers IPCI has now reported for both reporting periods.

Enough from me tonight...see ya's all tomorrow...and here's angelo's spreadsheet that prove the posted Bloomberg numbers for PAR/FocalinXR sales March through August...which were IPCI's fiscal Q2 and Q3>>>

[wimuskyfisherman]

swe77- I agree those numbers can be used as a gauge. But like Fred said, we need to be careful because they can be off.

Another thing that needs to be determined is how much of the raw revenue is profit. IPCI gets revenue from three sources:

1. Cost plus for manufacturing
2. % of profits
3. Cost recovery

I think the first thing we need to determine is how much of the raw Seroquel revenue is profit.

Here is a tidbit. Cost of goods sold this year(Seroquel costs plus)$587K. Cost of goods sold for Q3 was $376K. So I am going to go out on a limb and say that 15-25% of the MNK raw revenue number accounts for the amount they pay IPCI for product.